Trials / Completed
CompletedNCT00536731
Symbicort Rapihaler Therapeutic Equivalence Study
A 6-week, Phase III, Double-blind, Randomized, Multi-centre, Parallel-group Study Evaluating the Efficacy and Safety of 2 Actuations Symbicort®pMDI® 40/2.25 μg Twice Daily Compared With 1 Inhalation Symbicort Turbuhaler® 80/4.5 μg Twice Daily and 1 Inhalation Pulmicort®Turbuhaler® 100 μg Twice Daily
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 742 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the this study is to evaluate the efficacy and safety of 2 actuations Symbicort®pMDI® 40/2.25 μg twice daily compared with1 inhalation Symbicort Turbuhaler® 80/4.5 μg twice daily and 1 inhalation Pulmicort®Turbuhaler® 100 μg twice daily for 6 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Symbicort Turbuhaler | Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily |
| DRUG | Symbicort pMDI | Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily |
| DRUG | Pulmicort Turbuhaler | Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily |
Timeline
- Start date
- 2007-09-01
- Primary completion
- 2008-04-01
- Completion
- 2008-04-01
- First posted
- 2007-09-28
- Last updated
- 2012-08-15
- Results posted
- 2012-08-15
Locations
48 sites across 4 countries: Bulgaria, Czechia, Hungary, Poland
Source: ClinicalTrials.gov record NCT00536731. Inclusion in this directory is not an endorsement.